Molecular – genetic assay results and clinical, radiological features in patients with pulmonary tuberculosis by Malic, Alina
2
RESEARCH   STUDIES
Molecular–genetic assay results and clinical, radiological features  
in patients with pulmonary tuberculosis
Alina MALIC
Department of Pneumophtysiology, NicolaeTestemitsanu State University of Medicine and Pharmacy
Chisinau, the Republic of Moldova
Corresponding author: alina.malik@rambler.ru.  Manuscript received March 23, 2016; accepted April 05, 2016
Abstract
Background: Early diagnosis of smear-negative and multidrug-resistant tuberculosis represents a national priority, considering the fact that the Republic 
of Moldova ranks in the list of 30 high burden multidrug-resistance tuberculosis countries, with 26% rate of primary drug-resistance and 64% acquired 
drug-resistance. In April 2012 it was implemented the real-time fully automated diagnostic molecular test in 15 Moldovan districts and penitentiary 
institutions.  The new assay leads to enhance the tuberculosis early diagnosis, especially multidrug resistant tuberculosis.
Material and methods:  A retrospective, selective, descriptive and case-control study was performed using 361 new pulmonary tuberculosis patients, 
diagnosed and hospitalized in the Municipal Clinical Hospital of Phthysiopneumology of Chisinau city in the period of 01.01.2014-01.01.2015. The 
total sample was distributed in 2 groups: first group included 174 patients with pulmonary tuberculosis assessed by positive Xpert MTB/RIF assay and 
the second group included 187 patients with pulmonary tuberculosis assessed having negative Xpert MTB/RIF assay. Investigations were performed 
according to the National Clinical Protocols.
Results: The biggest rate of patients included in the research was detected by passive way, in the frame of examination of the symtomatic case: 111 (63.8%) 
patients of the 1st Group comparing with 87 (46.5%) in the 2nd Group, p<0.001.
Conclusions: The use of Xpert MTB/RIF technique must be improved in municipality Chisinau for achieving the international quality standards.
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Introduction
Tuberculosis is the most important public health threat 
in the Republic of Moldova, the country ranking among 30 
countries with the biggest burden of multidrug-resistance 
tuberculosis (MDR-TB) [1]. In overall, the primary MDR-TB 
increased four times in the Republic of Moldova in the period 
2003-2011 (6.0% – 2003, 9.9% – 2004, 13.4% – 2005, 19.4% 
– 2006, 17.8% – 2007, 24.0% – 2008, 22.2% – 2009, 25.7% – 
2010, 26.35% – 2011) and acquired drug-resistance two times 
(37.5% – 2003, 38% – 2004, 49.6% – 2005, 50.8% – 2006, 
52.3% – 2007, 59.0% – 2008, 64.85% – 2009, 67.8% – 2010, 
63.8% – 2011) [3]. MDR-TB represents a global concern and 
directly threatens disease-control efforts in many countries. 
Only 30.000 of nearly 500.000 new cases of MDR-TB every 
year are detected and reported [11]. The misdiagnosed cases 
contribute to thousands of deaths, nosocomial and commu-
nity transmission.
No much technology is available for an accurate detection 
of tuberculosis and its drug resistant forms, this fact being a 
major obstacle for improvement of tuberculosis control and 
reduction of the global burden of disease [12]. Microscopy 
alone, although inexpensive, misses many patients and detects 
only those with relatively advanced disease. Presently, only 
28% of registered tuberculosis cases are detected and reported 
as smear positive [3]. Undetected cases of tuberculosis increase 
the risk of disease transmission to the healthy population, 
endangering tuberculosis control. In low and middle income 
countries the high rate of HIV infection reduced the sensitivity 
of microscopy and increased the relevance of rapid diagnostic 
methods []. In recognition of these issues, substantial efforts 
were being made to strengthen laboratory capacities to dia-
gnose smear-negative and MDR-TB cases, including the use 
of solid and liquid culture, conventional drug-susceptibility 
testing, and line-probe assays. Unfortunately, these tests re-
quire extensive laboratory infrastructure and cannot be done 
outside of reference facilities. Recently, a real-time PCR assay 
for Mycobacterium tuberculosis that simultaneously detects 
rifampicine resistance was developed on the GeneXpert 
platform (Cepheid, Sunnyvale, CA, USA), which integrates 
sample processing and greatly simplifies testing [2]. Expected 
outcomes ensured by the national implementation of the new 
Xpert MTB/RIF technique are: early detection of infectious 
cases, isolation and precocious treatment of early detected new 
case, especially of MDR-TB, as well as infection control and 
improving the treatment success rate, that are considered the 
most efficient tools for interrupting the epidemiological chain 
of infectious transmission [16]. Starting from December 2010 
World Health Organization (WHO) strongly recommends 
the use of molecular-genetic Xpert MTB/RIF testing as the 
initial diagnostic test in adults and children presumed to have 
pulmonary MDR-TB, tuberculosis and HIV coinfection, or 
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TB meningitis [14]. In addition, WHO established conditional 
recommendations to use Xpert MTB/RIF test in adults and 
children presumed to have active TB (not especially MDR-
TB), or for testing the non-respiratory specimens targeting the 
diagnosis of extra pulmonary TB [15]. Always interpretations 
of this test must be correlated with laboratory and clinical data 
of the investigated patient. Published data established a high 
sensitivity among culture positive specimens on average 97.3% 
and among smear positive patients – 99.5%. The specificity 
comparing with non-tuberculosis patients was determined to 
be at 97.9% [2]. Error rates vary from 3 to 4%. The sensitivity 
is slightly decreased in a single sputum sample. Assessing 
the threshold of analytical sensitivity it was demonstrated 
that the biological sample must contain at least 131 colony 
forming units (CFU) per ml of sample with a confidence 
interval ranging from 106.2 CFU to 176.4 CFU [2]. In most 
of cases the detection of mycobacterial DNA depends on the 
collection procedure, storage, transportation, and technical 
errors. Insufficient volume of the specimen and insufficient 
concentration of the viable organisms are the most frequent 
causes of the negative results [2]. 
WHO Global TB program provides worldwide leader-
ship in strategic and technical aspects of TB control in order 
to eliminate TB. In 2011 the Stop TB Partnership started 
the ongoing of TB Xpert Project that provided 1.4 million 
Xpert MTB/RIF test cartridges and 220 Xpert instruments 
in 21 countries, the Republic of Moldova being one of them. 
Starting from April 2012, the Republic of Moldova received 
25 units of Xpert MTB/RIF equipment and 12.000 cartrid-
ges. Civilian TB services acquired 21 units, penitentiary TB 
services – 2 and AIDS services – Xpert MTB/RIF units of 
equipment. Preliminary results established some problems. 
The most important is the low sensitivity of Xpert MTB/RIF 
Assay that is compared with the sensitivity of conventional 
microbiological methods. More than one half of patients with 
tuberculosis are diagnosed through clinical-radiological me-
thods. Considering the WHO recommendations for aligning 
to international quality-assured standards it is necessary to 
improve the TB diagnostic algorithms.
Aim of the study consisted in evaluation of the Xpert 
MTB/RIF assay and diseases-related features (clinical and 
radiological) in patients with pulmonary tuberculosis. 
Material and methods
It was performed a retrospective, selective, descriptive and 
case-control study targeting peculiarities of pulmonary tubercu-
losis of 361 patients, treated in the Municipal Clinical Hospital 
of Phthysiopneumology of Chisinau city between 01.01.2014 
and 01.01.2015. The total number of cases was distributed in 
2 groups: 1st  Group (1st Group) included 174 patients with 
pulmonary tuberculosis assessed by positive Xpert MTB/RIF 
assay and second group (2nd Group ) included 187 patients with 
pulmonary tuberculosis assessed being negative at Xpert MTB/
RIF assay. Including criteria in the 1st group: age > 18 years old; 
patient with pulmonary tuberculosis was established as a new 
case; one smear positive GeneXpert MTB/RIF assay detecting 
MTB DNA; including criteria in the 2nd group: age > 18 years 
old; patient with pulmonary tuberculosis was established as a 
new case; one smear negative Xpert MTB/RIF assay. Collection 
of primary material involved the extraction of data from medical 
record forms. The individual schedule included information 
about: anamnesis, clinical examination, results of radiological 
investigations (chest radiography, plane tomography, and com-
puter tomography), results of microbiological investigations 
(bacterioscopy of the smear with Ziehl-Neelson coloration) and 
bacteriological examinations (culture on classic solid medium 
Lowenstein-Jensen and liquid medium). Investigations were 
performed according to the national clinical protocol. Statistical 
analysis methods used in the study were: comparative, synthesis, 
discriminate analyses. Mathematical and statistical assessments 
were carried out by checking the quantitative and qualitative 
features. Accumulated material was tabled in simple and complex 
groups. Statistical survey was performed using Microsoft Excel 
XP soft. The predictability value of each involved factor was 
calculated using two by two tables. Relative risk and confidence 
interval were calculated according to the established formula [4]. 
Results and discussion
Considering the fact that 361 patients were investigated 
through Xpert MTB/RIF, all of them confirmed with pulmo-
nary tuberculosis and only 174 had positive Xpert MTB/RIF. 
In the 1st group – 174 positive Xpert MTB/RIF cases included 
103 microscopic positive at Ziehl-Neelson staining cases. So, 
the sensitivity of microscopic method compared with Xpert 
MTB/RIF assay represents 59.2±3.72%, which means two 
times lower. The same 1st Group – 174 positive Xpert MTB/
RIF cases included 142 culture positive at Lowenstein-Jensen/
BACTEC Mycobacteria Growth Indicator Tube (MGIT) 960 
media. So, the sensitivity of culture method compared with 
Xpert MTB/RIF assay represents 81.6±2.93%. Rapid detection 
of rifampicine resistance was established at 63 (36.2±3.64%) 
cases from 174 positive Xpert MTB/RIF assay cases. On the 
other hand, in the second group, that included 187 Xpert 
MTB/RIF negative cases, 9 (4.8±1.56%) cases of them were 
microscopic positive at Ziehl-Neelson and 28 (14.9±2.60%) 
were culture positive at Lowenstein-Jensen/BACTEC MGIT 
media. So, Xpert MTB/RIF assay can’t replace conventional 
microbiological methods in actual epidemiological conditions 
of the Republic of Moldova. 
Case-management of patients 
 with pulmonary tuberculosis
According to the National Tuberculosis Program at least 
70% of all new tuberculosis cases must be detected by passive 
way, through microscopic smear examination of the sympto-
matic patient. Active way of detection is reserved only to high 
risk groups, annually investigated by chest Xray examination 
and also dangerous groups of 3 professional fields: health care 
staff, public service employees as well as educational staff. 
National TB Policy approved an examination algorithm of 
different groups of population (patients, adults and children 
with TB symptoms, HIV positive patients with TB symptoms, 
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vulnerable groups – homeless, drug-users, immunosupressed, 
medical staff, patients with suspected relapse, patients with cli-
nical signs of extrapulmonary TB) for TB diagnosis targeting 
the appropriate use of Xpert MTB/RIF assay. So, according 
to this, the sputum smear negative samples in highlighted 
groups of patients with clinical signs of TB (pulmonary TB 
or extra pulmonary TB) must be compulsorily investigated 
by Xpert MTB/RIF. 
The biggest rate of patients included in the research was 
detected by passive way, in the frame of examination of 
the symptomatic case: 111 (63.8±3.64%) patients of the 1st 
Group comparing with 87 (46.5±3.64%) in the 2nd Group, 
p<0.001. By active way of screening (targeted radiological 
investigation) were detected more frequently the patients 
from the 2nd Group 100 (53.5±3.64%) comparing with 63 
(36.2±3.64%) cases of the 1st Group, p<0.001. However, by 
passive way were detected more frequently the patients of the 
1st Group 111 (63.8±3.64%) comparing with the 2nd Group 
87 (46.5±3.64%), p<0.001. Data are shown in the table 1. 
Table 1
Distribution of detectional case-management
Screening 
way 
1st Group n=174 2nd Group n=187
P
n M± m (%) n M ± m (%)
Passive 111 63.8±3.64 87 46.5±3.64 <0.001
Active 63 36.2±3.64 100 53.5±3.64 <0.001
In one third of the cases the clinical diagnosis of pulmo-
nary tuberculosis was erroneously omitted due to similar as-
pects with other pathologies. Distributing patients by clinical 
onset masks, it was identified that pneumonia mask is more 
frequently involved in both groups, being more prevalent 
in the 1st Group 34 (26.4±3.87%) comparing with the 2nd 
Group 14 (11.2± 2.82%), p<0.05. No statistical differences 
were identified according to other type of TB masks (table 2).
Table 2
Distribution according to the clinical onset masks
Diagnosis 
1st Group n=174 2nd Group n=187
P
n M± m (%) n M ± m (%)
Pneumonia 34 26.4± 3.87 14 11.2± 2.82 <0.05
Bronchitis 6 4.7± 1.85 2 1.6± 1.12 >0.05
Laringitis 6 4.7± 1.85 1 0.8± 0.79 >0.05
Pleuresy 8 6.2± 2.12 1 0.8± 0.79 >0.05
Hemoptysis 4 3.1± 1.52 1 0.8± 0.79 >0.05
Note: LIT - limited pulmonary infiltrative tuberculosis, EIT – extensive 
pulmonary infiltrative tuberculosis, DT – disseminated pulmonary 
tuberculosis. FCv – fibro-cavitary pulmonary tuberculosis;
The period of time from the clinical onset till the confir-
mation of diagnosis was established similar distribution of 
patients in both groups. The period of one to three months 
between the clinical onset and Xpert MTB/RIF testing (esta-
blishing of TB diagnosis) was more prevalent in both groups: 
96 (55.2±3.77%) cases in the 1st Group and 108 (57.8±3.61%) 
- in the 2nd Group. Other delayed periods from the onset till 
the confirmation of TB diagnosis were similarly distributed 
within the groups (table 3).
Table 3
Distribution according to the delayed  
period till TB confirmation
Diagnosis 
 1st Group 2nd Group
P
n M± m(%) n M ± m (%)
14 days 29 16.7±2.82 24 12.8±2.44 >0.05
1 – 3 months 96 55.2±3.77 108 57.8±3.61 >0.05
3 – 6  months 38 21.8±3.13 43 22.9±3.07 >0.05
>6  months 11 6.3±1.84 12 6.4±1.79 >0.05
All above related data were directly linked to the establi-
shed clinical-radiological diagnosis of pulmonary tuberculo-
sis. So, pulmonary infiltrative tuberculosis was prevalent form 
in both groups: 159 (91.4%) of the 1st Group and 180 (96.3%) 
cases in the 2nd Group. Caseous pneumonia, the severest form 
of the pulmonary infiltrative tuberculosis was diagnosed in 5 
(2.9%) cases of the 1st Group. Disseminated tuberculosis was 
established in several cases of both groups - 14 (8.0%) cases of 
the 1st Group compared with 3 (1.6%) cases in the 2nd Group. 
Less diagnosed were the rest of forms (table 4).
Table 4
Clinical radiological forms of pulmonary tuberculosis
Diagnosis 
1st Group n=174 2nd Group n=187
P
n M± m (%) n M ± m (%)
PIT 159 91.4±2.12 180 96.3±1.38 >0.05
PDT 14 8.0±2.06 3 1.6±0.91 >0.05
NT 0 0 4 2.1±1.05 >0.05
FCv 1 0.6±0.57 0 0 >0.05
Note: PIT - pulmonary infiltrative tuberculosis, PDT – disseminated 
pulmonary tuberculosis. FCv –pulmonary fibrocavitary tuberculosis, 
NT – pulmonary nodular tuberculosis;
While assessing radio-morphological features of pulmo-
nary tuberculosis it was clearly identified the predomination 
of the destructive compound of the parenchyma in the 1st 
Group -58 (33.3%) cases compared with the 2nd Group - 18 
(9.6%) cases. The localization of the infectious process in both 
lungs was also predominated in the 1st group: 105 (60.3%) 
cases compared with 29 (15.5%) cases in the 2nd Group. The 
extensibility in more than three segments was argued more 
often in the 1st Group 104 (59.8%) compared with the 2nd 
Group 21 (11.2%) (table 5).
Table 5
Morpho-radiological features of pulmonary tuberculosis
Diagnosis 
1st Group n=174 2nd Group n=187
P
n M± m (%) n M ± m (%)
Destructions 58 33.3±3.57 18 9.6±2.15 <0.001
Dissemination 11 6.3±1.84 4 2.1±1.05 >0.05
Unilateral 69 39.7±3.70 158 84.5±2.64 <0.001
Bilateral 105 60.3±3.70 29 15.5±2.64 <0.001
Limited 70 40.2±3.71 166 88.8±2.30 <0.001
Extended 104 59.8±3.71 21 11.2±2.30 <0.001
Note: LIT – limited pulmonary infiltrative tuberculosis, EIT – 
extensive pulmonary infiltrative tuberculosis, DT – disseminated 
pulmonary tuberculosis. FCv – fibrocavitary pulmonary tuberculosis.
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Impact of disease related determinants on MTB 
detection by the positive Xpert MTB/RIF testing
Assessing statistically all above exposed data expressing 
case management, clinical-radiological characteristics and 
morpho-radiological features of patients with pulmonary 
tuberculosis with positive/negative results at the detection of 
MTB by Xpert MTB/RIF testing through multivariate logistic 
regression model was identified that all disease related factors 
have high impact on the positivity of MBT DNA detection: 
extensive infectious process (involving three and more seg-
ments), tuberculosis in both lungs, lung parenchyma destruc-
tions. Case management by passive way as well as pneumonia 
mask were revealed as factors with medium value (table 6).
Table 6
Relative risk forTB factors Xpert MTB/RIF  
assay positive patients
Factors Relative Risk 95% CI
Passive way of detection 1.45 1.15-1.82
Pneumonia mask 1.56 1.25-1.94
Lung destruction 1.87 1.55-2.26
Localisation in both lungs 2.47 1.71-3.56
Extensive pulmonary process 5.32 3.49-8.11
Conclusions
Passive case management and pneumonia mask were 
identified as factors with medium impact on Xpert MTB/RIF 
assay positive patients.
Extensive tuberculosis (involving three and more seg-
ments, localization of pathological changes in both lungs), 
parenchyma destructions have high impact in Xpert MTB/
RIF assay positive patients.
Xpert MTB/RIF assay leads to rapid identifing of possi-
ble multidrug-resistant TB (MDR TB) and early starting of 
effective treatment much sooner than waiting for results from 
other types of drug susceptibility testing.
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